Added to YB: 2025-10-28
Pitch date: 2025-10-24
IBRX [bullish]
ImmunityBio, Inc.
+240.32%
current return
Author Info
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases.
Market Cap
$5.9B
Pitch Price
$2.53
Price Target
N/A
Dividend
N/A
EV/EBITDA
-28.56
P/E
-14.31
EV/Sales
78.25
Sector
Biotechnology
Category
growth
Show full summary:
Immunity Bio: The Company That Could Save the World.
IBRX: IL-15 agonist Anktiva reverses lymphopenia (60% success in NSCLC, 80% maintain >1K cells/µL), tripling survival vs standard care. Platform targets immune exhaustion from COVID/aging. CEO Soon sold 2 biotechs for $7.6B, owns 50%+. High risk/insolvent but massive upside if platform scales.
Read full article (9 min)